Treatment Decision Impact of OncotypeDX™ in HR+, N- Breast Cancer Patients

NACompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

January 31, 2011

Primary Completion Date

February 29, 2012

Study Completion Date

May 31, 2012

Conditions
Breast Cancer
Interventions
DEVICE

Oncotype DX breast cancer test

The Oncotype DX breast cancer test measures the expression of 21 genes of an individual tumor to generate an Recurrence Score result that quantifies the magnitude of chemotherapy benefit and the likelihood of recurrence for early-stage breast cancer patients.

Trial Locations (6)

6250

Centre Azuréen de Cancérologie, Mougins

25030

CHRU Besançon, Besançon

34298

Centre Val d'Aurelle, Montpellier

54000

Centre d'Oncologie Médicale de Gentilly, Nancy

63011

Centre Jean Perrin, Clermont-Ferrand

75020

Hôpital TENON, Paris

Sponsors
All Listed Sponsors
collaborator

Registrat-Mapi

OTHER

lead

Genomic Health®, Inc.

INDUSTRY

NCT01446185 - Treatment Decision Impact of OncotypeDX™ in HR+, N- Breast Cancer Patients | Biotech Hunter | Biotech Hunter